Table 2.
Univariate and multivariate analysis for prediction of PFS and OS in patients with advanced NSCLC receiving immunotherapy
| Variables | PFS | OS | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | |||||||||
| HR | 95% CI | P | HR | 95% CI | P | HR | 95% CI | P | HR | 95% CI | P | |
| % PD-L1 + CD4 + | 0.98 | 0.94–1.01 | 0.27 | 0.97 | 0.93–1.01 | 0.28 | ||||||
| % PD-L1 + CD8 + | 0.95 | 0.88–1.02 | 0.18 | 0.96 | 0.9–1.03 | 0.31 | ||||||
| % PD-L1 + CD8 + NK | 0.96 | 0.91–1.02 | 0.23 | 0.97 | 0.91–1.04 | 0.42 | ||||||
| % PD-L1 + CD14 + | 0.97 | 0.96–0.99 | 0.002 | 0.98 | 0.96–0.99 | 0.001 | 0.97 | 0.95–0.99 | 0.02 | 0.98 | 0.96–0.99 | 0.02 |
| % PD-L1 + Neutrophil | 0.96 | 0.93–0.99 | 0.04 | 0.94 | 0.91–0.98 | 0.04 | ||||||
| % PD-L1 + PLTs | 0.98 | 0.95–1 | 0.06 | 0.97 | 0.94–1.1 | 0.058 | ||||||
| % PD-L1 + PMPs | 0.89 | 0.81–0.99 | 0.04 | 0.89 | 0.81–0.99 | 0.02 | 0.95 | 0.88–1.04 | 0.27 | |||
| pg/ml sPD-L1 | 0.98 | 0.94–1.03 | 0.56 | 1 | 0.96–1.05 | 0.75 | ||||||
| % TPS | 0.99 | 0.98–1 | 0.14 | 0.98 | 0.98–0.99 | 0.031 | 0.99 | 0.98–1 | 0.04 | |||
CI Confidence interval, HRHazard Ratio, OS Overall survival, PMPs Platelet microparticles, PFS Progression free survival, PLTs Platelets, TPS tumor proportion score